The global recombinant DNA technology market size was estimated to be USD 148.71 billion in 2023 and is expected to reach at USD 345.7 billion by 2033 with a CAGR of 7.97% during the forecast period 2023-2033. Rising investment in research for development of recombinant products, increasing mergers & acquisitions by key market players, technological advancements in recombinant DNA technologies, increasing genetic disorder, growing demand for early detection of disease, rising development of genetically modified crops to improve both yield & resistance to pests or herbicides, rising application of RDT in agriculture & food, and growing research & development activities are the key factors propelling the market growth
Increasing product launches by major market players is predicted to boost the market growth during the forecast period. For instance, in March 2022, PreHevbrio (Recombinant Hepatitis B Vaccine) was just introduced in the US by VBI Vaccines Inc. In order to avoid infection, this vaccine, which is especially made for individuals 18 years of age and older, offers defense against all recognized subtypes of the hepatitis B virus (HBV).
By Product, Component was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising developments for efficient protein expression, growing development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO), and rising technological advancements. Additionally, Non-medical is predicted to grow at fastest CAGR during the forecast period owing to the increasing development of genetically modified crops and increasing product launches. For instance, in September 2021, A collaboration between Sanatech Seed Co, and researchers from the University of Tsukuba led to the creation of a novel type of tomatoes utilizing CRISPR/Cas9 gene-editing technology. Initially, the company distributed complimentary tomato seeds to approximately 4,200 individuals. Subsequently, they commenced the commercial sale of genetically modified tomatoes.
By Application, Food and Agriculture was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising development of genetically modified crops, increasing research & development activities, and growing launch of genetically modified crops. For instance, in August 2021, In Brazil, Corteva Inc. introduced a genetically modified soybean seed known as Conkesta E3 to the market. The European Union Commission recently granted approval for these soybeans, allowing the export of grains derived from Conkesta E3 soybean seeds grown in Brazil to the European market for both food and feed purposes. Additionally, Health and disease is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of chronic & infectious diseases.
By End User, Academic and Government Research Institutes was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising prevalence of chronic & infectious diseases and rising research & development activities for the formulation of therapies & treatments. For instance, in January 2022, Jiangsu Recbio Technology Co. Ltd. successfully created a Recombinant COVID-19 Vaccine named ReCOV. Following Phase 1 studies that demonstrated robust immunogenicity and safety data, along with effective cross-neutralization against Omicron and Delta variants, the vaccine obtained authorization in the Philippines. The company plans to expedite Phase II/III clinical development at multiple international centers worldwide during the upcoming months of 2022. Additionally, Biotechnology and pharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to increasing introduction of genetically modified products and rising technological advancements.
North America region is anticipated to witness the highest revenue share during the forecast period owing to the increasing research & development activities. For instance, in May 2022, PharmaJet announced that the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), awarded a funding of USD 12 million to its partner, the Institute for Molecular Medicine (IMM). The grant is intended to support clinical trials focused on beta-amyloid vaccines for the prevention of Alzheimer's disease (AD), utilizing DNA and recombinant proteins as the basis for the vaccines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing launch of genetically modified products and rising product approvals by regulatory bodies. For instance, in February 2022, VBI Vaccines Inc. obtained a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding their 3-antigen hepatitis B (HBV) vaccine, known as PreHevbri. This vaccine, designed for active immunization in adults, aims to protect against all identified subtypes of the hepatitis B virus.
Increasing product launches by major market players is predicted to boost the market growth during the forecast period. For instance, in March 2022, PreHevbrio (Recombinant Hepatitis B Vaccine) was just introduced in the US by VBI Vaccines Inc. In order to avoid infection, this vaccine, which is especially made for individuals 18 years of age and older, offers defense against all recognized subtypes of the hepatitis B virus (HBV).
By Product, Component was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising developments for efficient protein expression, growing development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO), and rising technological advancements. Additionally, Non-medical is predicted to grow at fastest CAGR during the forecast period owing to the increasing development of genetically modified crops and increasing product launches. For instance, in September 2021, A collaboration between Sanatech Seed Co, and researchers from the University of Tsukuba led to the creation of a novel type of tomatoes utilizing CRISPR/Cas9 gene-editing technology. Initially, the company distributed complimentary tomato seeds to approximately 4,200 individuals. Subsequently, they commenced the commercial sale of genetically modified tomatoes.
By Application, Food and Agriculture was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising development of genetically modified crops, increasing research & development activities, and growing launch of genetically modified crops. For instance, in August 2021, In Brazil, Corteva Inc. introduced a genetically modified soybean seed known as Conkesta E3 to the market. The European Union Commission recently granted approval for these soybeans, allowing the export of grains derived from Conkesta E3 soybean seeds grown in Brazil to the European market for both food and feed purposes. Additionally, Health and disease is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of chronic & infectious diseases.
By End User, Academic and Government Research Institutes was the highest revenue-grossing segment in the global recombinant DNA technology market in 2022 owing to rising prevalence of chronic & infectious diseases and rising research & development activities for the formulation of therapies & treatments. For instance, in January 2022, Jiangsu Recbio Technology Co. Ltd. successfully created a Recombinant COVID-19 Vaccine named ReCOV. Following Phase 1 studies that demonstrated robust immunogenicity and safety data, along with effective cross-neutralization against Omicron and Delta variants, the vaccine obtained authorization in the Philippines. The company plans to expedite Phase II/III clinical development at multiple international centers worldwide during the upcoming months of 2022. Additionally, Biotechnology and pharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to increasing introduction of genetically modified products and rising technological advancements.
North America region is anticipated to witness the highest revenue share during the forecast period owing to the increasing research & development activities. For instance, in May 2022, PharmaJet announced that the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), awarded a funding of USD 12 million to its partner, the Institute for Molecular Medicine (IMM). The grant is intended to support clinical trials focused on beta-amyloid vaccines for the prevention of Alzheimer's disease (AD), utilizing DNA and recombinant proteins as the basis for the vaccines. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing launch of genetically modified products and rising product approvals by regulatory bodies. For instance, in February 2022, VBI Vaccines Inc. obtained a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding their 3-antigen hepatitis B (HBV) vaccine, known as PreHevbri. This vaccine, designed for active immunization in adults, aims to protect against all identified subtypes of the hepatitis B virus.
Segmentation: Recombinant DNA Technology Market Report 2022-2033
Recombinant DNA Technology Market Analysis & Forecast By Product 2022-2033 (Revenue USD Bn)
Component
- Cloning Vector
- Expression System
Non-medical
- Specialty Chemicals
- Biotech Crops
Medical
- Human Protein
- Vaccine
- Therapeutic Agent
Recombinant DNA Technology Market Analysis & Forecast By Application 2022-2033 (Revenue USD Bn)
- Health and Disease
- Food and Agriculture
- Environment
- Others
Recombinant DNA Technology Market Analysis & Forecast By End-user 2022-2033 (Revenue USD Bn)
- Academic and Government Research Institutes
- Biotechnology and Pharmaceutical Companies
Recombinant DNA Technology Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Recombinant DNA Technology Market: Product Estimates & Trend Analysis
8. Recombinant DNA Technology Market: Application Estimates & Trend Analysis
9. Recombinant DNA Technology Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Recombinant DNA Technology Market
12. Europe Global Recombinant DNA Technology Market
13. Asia Pacific Global Recombinant DNA Technology Market
14. Latin America Global Recombinant DNA Technology Market
15. MEA Global Recombinant DNA Technology Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi Pasteur Limited
- Merck KgaA
- Genentech Inc.
- GlaxoSmithKline plc.
- Eli Lilly and Company
- Pfizer Inc.
- Janssen Pharmaceutical Inc.
- GenScript
- New England Biolabs
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 148.7 Billion |
| Forecasted Market Value ( USD | $ 345.7 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
